Search

Author/Creator Newell, David R.

1. 2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase. Issue 6 (22nd May 2020)

Authors:
Matheson, Christopher J.; Coxon, Christopher R.; Bayliss, Richard; Boxall, Kathy; Carbain, Benoit; Fry, Andrew M.; Hardcastle, Ian R.; Harnor, Suzannah J.; Mas-Droux, Corine; Newell, David R.; Richards, Mark W.; Sivaprakasam, Mangaleswaran; Turner, David; Griffin, Roger J.; Golding, Bernard T.; C...
Journal:
RSC medicinal chemistry
Issue:
Volume 11:Issue 6(2020)
Page Start:
707
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. Issue 4 (25th January 2016)

Authors:
Reuillon, Tristan; Alhasan, Sari F.; Beale, Gary S.; Bertoli, Annalisa; Brennan, Alfie; Cano, Celine; Reeves, Helen L.; Newell, David R.; Golding, Bernard T.; Miller, Duncan C.; Griffin, Roger J.
Journal:
Chemical science
Issue:
Volume 7:Issue 4(2016:Apr.)
Page Start:
2821
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. (March 2016)

Authors:
Haagensen, Emma J.; Thomas, Huw D.; Mudd, Clare; Tsonou, Elpida; Wiggins, Ceri M.; Maxwell, Ross J.; Moore, Jonathan D.; Newell, David R.
Journal:
European journal of cancer
Issue:
Volume 56(2016)
Page Start:
69
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. (March 2016)

Authors:
Haagensen, Emma J.; Thomas, Huw D.; Mudd, Clare; Tsonou, Elpida; Wiggins, Ceri M.; Maxwell, Ross J.; Moore, Jonathan D.; Newell, David R.
Journal:
European journal of cancer
Issue:
Volume 56(2016)
Page Start:
69
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Issue 12 (9th January 2019)

Authors:
Chen, Lindi; Pastorino, Fabio; Berry, Philip; Bonner, Jennifer; Kirk, Calum; Wood, Katrina M.; Thomas, Huw D.; Zhao, Yan; Daga, Antonio; Veal, Gareth J.; Lunec, John; Newell, David R.; Ponzoni, Mirco; Tweddle, Deborah A.
Journal:
International journal of cancer
Issue:
Volume 144:Issue 12(2019)
Page Start:
3146
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases1. Issue 18 (14th May 2015)

Authors:
Miller, Duncan C.; Carbain, Benoit; Beale, Gary S.; Alhasan, Sari F.; Reeves, Helen L.; Baisch, Ulrich; Newell, David R.; Golding, Bernard T.; Griffin, Roger J.
Journal:
Organic & biomolecular chemistry
Issue:
Volume 13:Issue 18(2015)
Page Start:
5279
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Searching for Dual Inhibitors of the MDM2‐p53 and MDMX‐p53 Protein–Protein Interaction by a Scaffold‐Hopping Approach. (19th December 2014)

Authors:
Zaytsev, Andrey; Dodd, Barry; Magnani, Matteo; Ghiron, Chiara; Golding, Bernard T.; Griffin, Roger J.; Liu, Junfeng; Lu, Xiaohong; Micco, Iolanda; Newell, David R.; Padova, Alessandro; Robertson, Graeme; Lunec, John; Hardcastle, Ian R.
Journal:
Chemical biology & drug design
Issue:
Volume 86:Number 2(2015:Aug.)
Page Start:
180
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗